Skip to content
  • About us
    • Overview
    • Our founders
    • Careers
  • Our pipeline
    • Development pipeline
    • Netazepide
      • Background
      • Studies
      • Further studies
    • Ceclazepide
    • TR4
    • TR8
  • Trio Medicines Logo
  • Our publications
  • Contact us
Previous Next

Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist.

Boyce M and Thomsen L. Gastric neuroendocrine tumours: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist. Scand J Gastroenterol 2015; 50: 550–559.

myarzi12019-03-26T13:16:38+00:00Netazepide|

Share This Story, Choose Your Platform!

FacebookTwitterLinkedInRedditGoogle+TumblrPinterestVkEmail